Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2017 (2017), Article ID 4382518, 2 pages

Nonmotor Symptoms of Parkinson’s Disease

1Department of Neurology, Changhua Christian Hospital, Changhua, Taiwan
2Department of Neurology, RHON Kliniken, Lehrkrankenhaus Philipps Universität, Marburg, Germany
3Department of Anatomy and Neuroscience, School of Medicine, University of Osijek, Osijek, Croatia
4Neurocognitive Behavior Center, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
5Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence and IRCCS Don Gnocchi Firenze, Florence, Italy
6Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
7Department of Master’s Program in Neurology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
8Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

Correspondence should be addressed to Yuan-Han Yang

Received 14 February 2017; Accepted 16 February 2017; Published 2 March 2017

Copyright © 2017 Shey-Lin Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The classical clinical features of the Parkinson’s disease (PD) are the motor disorders, in which parkinsonism is defined by the presence of bradykinesia plus at least one additional motor sign, rest tremor, rigidity, or impaired postural reflexes, the well-known clinical criteria [1]. However in the recent decades, scientists and physicians have received a lot of attention of the relevance and frequency of nonmotor symptoms (NMS) independently or dependently along with the motor symptoms [2, 3]. In PD, in general, in its different stages of disease it could be found that overall 98.6% of the PD patients have reported the presence of one or several NMS [4]. Those reported NMS might include olfactory dysfunction, neuropsychiatric manifestations as depression or cognitive impairments, sleep disorders as rapid eye movement behavior disorder, autonomic dysfunctions as gastrointestinal disorders, postural hypotension or urinary disorders, and fatigue pain.

Among NMS, cognitive impairment is one of the most common and significant aspects of PD. The cognitive deficits such as executive deficit or visuospatial disturbances could seriously affect the quality of life, reduce life expectancy, prolong the duration of hospitalization, or therefore increase burdens of caregiver [5, 6]. The pathophysiology of cognitive deficits in PD is complex perhaps due to its complexity and variability from patient to patient. Furthermore, the treatment of cognitive impairment including pharmacotherapy and nonpharmacotherapy (e.g., cognitive training) is still with the limited evidence [7, 8].

Gastrointestinal dysfunction might occur at all stages of PD, often preceding the onset of central motor symptom. Evidence for abnormal α-synuclein throughout the enteric nervous system is growing [9]. Different gastrointestinal symptoms, such as dental problem, drooling, dysphagia, gastroparesis, gastroesophageal reflux, constipation, difficult defecation, or loss of weight, are frequent events in all the stages of Parkinson’s disease. The treatment of these symptoms is still variable and inconclusive.

In addition to pharmacotherapy, deep brain stimulation (DBS) is a powerful surgical treatment for many aspects of Parkinson disease but lacks consensus inasmuch as the impact of the DBS procedure on executive brain functions [10].

People with PD may experience felt stigma, such as shame, embarrassment, and disgrace, and enacted stigma when encountering responses of others, such as staring, questioning, and avoiding, to their visible features of movement and communication difficulties [11]. The qualitative research may allow a better understanding of a subjective symptom such as stigma in parkinsonian patients from an intercultural and a social point of view.

In order to reach such purposes, this special issue will mainly focus on nonmotor symptoms of PD with its content including above-mentioned topics. We sincerely hope that this special issue will provide interesting new data as well as comprehensive up-to-date reviews for all readers.

Shey-Lin Wu
Rajka M. Liscic
SangYun Kim
Sandro Sorbi
Yuan-Han Yang


  1. A. J. Hughes, S. E. Daniel, Y. Ben-Shlomo, and A. J. Lees, “The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service,” Brain, vol. 125, no. 4, pp. 861–870, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Schrag, M. Jahanshahi, and N. Quinn, “What contributes to quality of life in patients with Parkinson's disease?” Journal of Neurology Neurosurgery and Psychiatry, vol. 69, no. 3, pp. 308–312, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. K. R. Chaudhuri, D. G. Healy, and A. H. V. Schapira, “Non-motor symptoms of Parkinson's disease: diagnosis and management,” Lancet Neurology, vol. 5, no. 3, pp. 235–245, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. M. B. Stern, A. Lang, and W. Poewe, “Toward a redefinition of Parkinson's disease,” Movement Disorders, vol. 27, no. 1, pp. 54–60, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. T. C. Buter, A. Van Den Hout, F. E. Matthews, J. P. Larsen, C. Brayne, and D. Aarsland, “Dementia and survival in Parkinson disease: a 12-year population study,” Neurology, vol. 70, no. 13, pp. 1017–1022, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. M. A. Hely, W. G. J. Reid, M. A. Adena, G. M. Halliday, and J. G. L. Morris, “The sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years,” Movement Disorders, vol. 23, no. 6, pp. 837–844, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Petrelli, S. Kaesberg, M. T. Barbe et al., “Effects of cognitive training in Parkinson's disease: a randomized controlled trial,” Parkinsonism and Related Disorders, vol. 20, no. 11, pp. 1196–1202, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Mamikonyan, S. X. Xie, E. Melvin, and D. Weintraub, “Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study,” Movement Disorders, vol. 30, no. 7, pp. 912–918, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. M. G. Cersosimo, G. B. Raina, C. Pecci et al., “Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms,” Journal of Neurology, vol. 260, no. 5, pp. 1332–1338, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. C. E. Morrison, J. C. Borod, M. F. Brin et al., “A Program for Neuropsychological Investigation of Deep Brain Stimulation (PNIDBS) in movement disorder patients: development, feasibility, and preliminary data,” Neuropsychiatry, Neuropsychology and Behavioral Neurology, vol. 13, no. 3, pp. 204–219, 2000. View at Google Scholar · View at Scopus
  11. D. Rao, S. W. Choi, D. Victorson et al., “Measuring stigma across neurological conditions: the development of the stigma scale for chronic illness (SSCI),” Quality of Life Research, vol. 18, no. 5, pp. 585–595, 2009. View at Publisher · View at Google Scholar · View at Scopus